– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned –– Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain on Track –– Top-Line Data from Phase 2 CALLIPER Trial Expected in April 2025 –– Webcast to be Held Today, November 7, at 8:00 am ET –NEW YORK, Nov. 7, 2024 ...